This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Health Winners & Losers

Shares of biotech Iomai (IOMI) soared nearly 25.3% to $6.39 after the company said it will receive a contract from the Department of Health and Human Services to develop a patch to improve the efficacy of small amounts of flu vaccine, to help cover more individuals in the event of a pandemic.

The company could receive research costs plus a fix fee totaling $128 million. The department has already allotted $14.5 million to cover performance under the contract through March 31, 2008, Iomai says.

Shares of drug developer Xoma (XOMA) jumped 6.4% to $2.50 after the company said it's expanding its collaboration with Schering-Plough (SGP) in the development of antibodies to treat cancer and immune diseases.

Shares of Angiotech Pharmaceuticals (ANPI) gained 5% to $9.03 after a Dutch court ruled in favor of the company and partner Boston Scientific (BSX) in a patent dispute with Conor Medsystems (CONR).

Shire's (SHPGY) shares were up 1.4% to $64.45 after the pharmaceuticals company said it received regulatory approval for its ulcerative colitis drug Lialda.

Shares of Neurocrine Biosciences (NBIX) gained 5% to $12.33 after the stock was upgraded to overweight from equal weight by Lehman Brothers health care analyst Jim Birchenough.

Among other health stock winners Wednesday were GlaxoSmithKline (GSK), up 1.3% to $55.23; Johnson & Johnson (JNJ), 1% higher to $67.22; Abbott (ABT), rising 1.4% to $51.32; Wyeth (WYE) up 1.4% to $51.17; Novogen (NVGN), gaining 4.5% to $12.10; and Geron (GERN) growing 3.7% to $8.97.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs